
Bristol Myers Squibb’s investigational deucravacitinib drug, for the treatment of moderate-to-severe plaque psoriasis, has shown positive results in two Phase …
Aiforia deal to expand access to pathology AI
SMC accepts atogepant for acute migraine treatment in Scotland
New CCO Ogburn joins Cori Clinical

